ASCO GUIDELINES Bundle

HR-Positive, HER2-Negative Metastatic Breast Cancer Endocrine Treatment and Targeted Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475466

Contents of this Issue

Navigation

Page 1 of 7

Introduction ➤ The purpose of this guideline is to update recommendations of the American Society of Clinical Oncology (ASCO) systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. a ➤ Specifically, it: • provides a new recommendation for the use of alpelisib in the treatment of patients with hormone receptor-positive metastatic breast cancer • addresses the role of biomarkers in treatment selection for this patient population and • amends prior recommendations concerning the use of CDK4/6 inhibitors in the treatment of these patients. ➤ Note that this guideline provides recommendations for endocrine therapy and targeted therapy, including CDK 4/6 and PI3 kinase inhibition for hormone receptor-positive metastatic breast cancer patients. A companion guideline b provides recommendations for use of chemo-and targeted therapy for patients with HER2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative a Rugo HS, et al. J Clin Oncol 34:3069-103, 2016. b Moy B et al. J Clin Oncol. doi:10.1200/JCO.21.01374.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - HR-Positive, HER2-Negative Metastatic Breast Cancer Endocrine Treatment and Targeted Therapy